Why Biotech Stocks Don't Pay Dividends
Dividend paying stocks are a staple in market-beating investment portfolios, but dividend investors don’t have very many options when it comes to investing in the biotechnology sector. Out of the largest biotechnology stocks, only Amgen has made the decision to reward investors with dividend payments.
That’s likely frustrating to dividend investors. After all, biotech stocks like Gilead Sciences generate billions of dollars in sales from key drugs and boast enviable cash-flow boosting margins that would seem to support sending at least some of their profit back to shareholders. However, there are valid reasons that these companies choose to stockpile cash rather than pay a dividend, so we put the question of why biotech stocks don’t pay dividends to Motley Fool health care analyst Michael Douglass and health care contributor Todd Campbell. Watch the following video to learn what they think are the real reasons behind biotechnology’s stingy dividend payout policy.
This coming blockbuster will make even Amgen jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Why Biotech Stocks Don’t Pay Dividends originally appeared on Fool.com.
Todd Campbell owns shares of Gilead Sciences and Johnson & Johnson. Todd owns E.B Capital Markets, LLC. E.B. Capital’s clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow’s clients don’t have positions in the companies mentioned. Michael Douglass owns Gilead Sciences, Celgene, and Johnson & Johnson. ;The Motley Fool recommends Gilead Sciences, Celgene, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 – 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.
Read article here:
Why Biotech Stocks Don't Pay Dividends
